PVLA PALVELLA THERAPEUTICS, INC.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1583648 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-113.9%
TTM EPS YoY-120.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-63.4%
ROA-49.0%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets17.3%
Debt / equity0.00x
Current ratio16.01x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.57x
Accruals ratio-20.8%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $10.82M | $12.47M | $9.33M | $7.12M | $6.53M | $5.12M | $4.07M | $2.54M |
| SG&A expense | $11.90M | $8.93M | $5.52M | $4.18M | $3.65M | $4.13M | $3.80M | -$5.20M |
| Operating income | -$22.73M | -$21.41M | -$14.86M | -$11.30M | -$10.18M | -$9.25M | -$7.87M | -$1.48M |
| Interest expense | — | — | — | $0 | $0 | $0 | — | $181,000 |
| Pretax income | -$24.64M | -$21.87M | -$15.77M | -$12.71M | -$11.35M | -$9.47M | -$8.19M | -$3.95M |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$24.64M | -$21.87M | -$15.77M | -$12.71M | -$11.35M | -$9.47M | -$8.19M | -$6.07M |
| EPS (basic) | -1.70 | -1.52 | -1.20 | — | -1.03 | -0.86 | -0.74 | — |
| EPS (diluted) | -1.70 | -1.52 | -1.20 | — | -1.03 | -0.86 | -0.74 | — |
| Weighted avg. shares (diluted) | 14.53M | 14.36M | 13.09M | — | 11.06M | 11.05M | 11.01M | — |
| Banking | ||||||||
| Net interest income | $2.55M | $1.97M | $1.07M | $520,000 | $628,000 | $690,000 | $752,000 | $281,000 |
| Balance sheet | ||||||||
| Cash & equivalents | $193.30M | $187.80M | $206.39M | $57.98M | $63.57M | $70.43M | $75.63M | $83.60M |
| Short-term investments | $43.38M | $62.78M | $55.46M | $0 | — | — | — | — |
| Receivables | — | — | — | $0 | $0 | $0 | $0 | $358,000 |
| Current assets | $238.97M | $253.03M | $263.23M | $58.99M | $66.94M | $73.75M | $79.44M | $88.23M |
| Total assets | $239.40M | $253.51M | $263.76M | $59.56M | $66.94M | $73.75M | $79.44M | $88.23M |
| Current liabilities | $14.93M | $11.95M | $9.12M | $11.34M | $10.31M | $9.62M | $8.98M | $12.04M |
| Total liabilities | $41.48M | $36.64M | $31.45M | $31.58M | $28.25M | $25.97M | $23.86M | $25.63M |
| Shareholders' equity | $197.92M | $216.87M | $232.31M | $27.98M | $38.68M | $47.78M | $55.58M | $62.61M |
| Shares outstanding | 14.61M | 14.40M | 14.31M | 12.38M | 11.09M | 11.06M | 11.02M | 11.01M |
| Cash flow statement | ||||||||
| Operating cash flow | -$14.43M | -$12.85M | -$10.86M | -$4.93M | -$7.88M | -$5.43M | -$6.77M | -$2.51M |
| Investing cash flow | $19.57M | -$7.03M | -$55.44M | — | $0 | $0 | $0 | — |
| Financing cash flow | $452,000 | $1.28M | $214.73M | -$49,000 | $242,000 | $349,000 | -$1.20M | $87.09M |
| Stock-based compensation | $5.42M | $5.16M | $3.38M | $2.08M | $1.79M | $1.43M | $1.09M | -$393,000 |
Free plan shows the latest 8 periods; Pro shows all 53 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.